Patent: 10,377,832
✉ Email this page to a colleague
Summary for Patent: 10,377,832
| Title: | Modified glycoproteins |
| Abstract: | Modified glycoproteins, and methods of making and using such modified glycoproteins, are described. |
| Inventor(s): | Washburn; Nathaniel (Littleton, MA), Meador, III; James (Framingham, MA), Bosques; Carlos J. (Arlington, MA), Bulik; Dorota A. (Malden, MA), Bhatnagar; Naveen (Framingham, MA), Brown; Julia (Somerville, MA), Markowitz; Lynn (Waltham, MA), Prabbhakar; Sathya (Boxborough, MA) |
| Assignee: | Momenta Pharmaceuticals, Inc. (Cambridge, MA) |
| Application Number: | 15/497,057 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,377,832
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | REOPRO | abciximab | Injection | 103575 | December 22, 1994 | ⤷ Start Trial | 2037-04-25 |
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | November 26, 1997 | ⤷ Start Trial | 2037-04-25 |
| Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | December 10, 1997 | ⤷ Start Trial | 2037-04-25 |
| Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | May 12, 1998 | ⤷ Start Trial | 2037-04-25 |
| Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | January 02, 2003 | ⤷ Start Trial | 2037-04-25 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
